. 2016 Sep 28;34(3):160–167. doi: 10.3857/roj.2016.01970

Table 3.

Phase 3 randomized clinical trials investigating role of radiotherapy in hepatocellular carcinoma

NCT no.	Estimated enrollment	Arms	Primary outcome measures	Secondary or other outcome measures	Estimated primary completion date
NCT02794337	386	Arm 1: DEB TACE	In-field PFS	CSS, tumor response, QoL, toxicity	Jan 2019
NCT02794337	386	Arm 2: DEB TACE & SBRT	In-field PFS	CSS, tumor response, QoL, toxicity	Jan 2019
NCT01963429	144	Arm 1: RFA	local PFS	DFS, OS	Dec 2018
NCT01963429	144	Arm 2: Proton beam therapy	local PFS	DFS, OS	Dec 2018
NCT01730937	368	Arm 1: Sorafenib tosylate	OS	TTP, PFS, toxicity, QoL, quality adjusted survival	Jun 2016
NCT01730937	368	Arm 2: SBRT and sorafenib tosylate	OS	TTP, PFS, toxicity, QoL, quality adjusted survival	Jun 2016
NCT02762266	160	Arm 1: TACE	FFLP	PFS, OS	-
NCT02762266	160	Arm 2: SBRT	FFLP	PFS, OS	-
NCT02511522	60	Arm 1: Best supportive care	Improvement of pain/discomfort	Adverse event, 90-day survival, QoL, reduction of opioid use	Jul 2018
NCT02511522	60	Arm 2: Best supportive care & RT	Improvement of pain/discomfort		Jul 2018
NCT02323360	80	Arm 1: SBRT	Local control	PFS, OS, toxicity	Nov 2016
NCT02323360	80	Arm 2: TACE	Local control	PFS, OS, toxicity	Nov 2016
NCT02125396	150	Arm 1: RT	OS	Recurrence rate	Dec 2017
NCT02125396	150	Arm 2: TACE	OS	Recurrence rate	Dec 2017

DEB, drug eluting bead; TACE, trans-arterial chemoembolization; SBRT, stereotactic body radiotherapy; PFS, progression free survival; CSS, cause specific survival; QoL, quality of life; RFA, radiofrequency ablation; DFS, disease free survival; OS, overall survival; TTP, time to progression; FFLP, freedom from local progression; RT, radiotherapy.